Lupus Nephritis Clinical Trials in San Francisco, California

5 studies are recruiting for lupus nephritis in San Francisco, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. VIBRANT: VIB4920 for Active Lupus Nephritis

   This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of California San Francisco School of Medicine: Lupus Clinic and Rheumatology Clinical Research Center, San Francisco, California

   Locations

   17 in total

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT05201469 on ClinicalTrials.gov

2. The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

   The study is a 1-year 2-part double-blinded placebo controlled 2-arm clinical trial. Treatment arms are (1) MMF dosed as per body-surface area (MMFBSA; 600mg/m2 body surface area per dose about every 12 hours) and (2) pharmacokinetically-guided precision-dosing of MMF (MMFPK; MMF dosed twice daily …

   Stage

   Phase 2

   Ages

   8 to 20

   Site

   University of California, San Francisco, San Francisco, California

   Locations

   19 in total

   Run by

   Children's Hospital Medical Center, Cincinnati

   See if you can join NCT05538208 on ClinicalTrials.gov

3. A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis

   The primary objective of this trial is to evaluate the efficacy and safety of FT819, comprised of allogeneic T cells that express a CD19-targeted CAR, following bendamustine administration in participants with refractory moderate-to-severe lupus nephritis, as assessed by the proportion of participa…

   Stage

   Phase 2

   Ages

   12 to 70

   Site

   University of California San Francisco, San Francisco, California

   Locations

   12 in total

   Run by

   Fate Therapeutics

   See if you can join NCT07570862 on ClinicalTrials.gov

4. A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

   This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN). It will also evaluate open label…

   Stage

   Phase 2

   Ages

   5 to 17

   Site

   UCSF Benioff Childrens Hospital, San Francisco, California

   Locations

   43 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT05039619 on ClinicalTrials.gov

5. A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

   This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary medicinal product (AMP) in participants with moderate-to-severe active systemic lupus erythematosus (SLE) with or without nephritis, antine…

   Stage

   Phase 1

   Ages

   12 to 70

   Site

   University of California San Francisco, San Francisco, California

   Locations

   21 in total

   Run by

   Fate Therapeutics

   See if you can join NCT06308978 on ClinicalTrials.gov